Handa Pharmaceuticals, Inc. (6620)
TWSE
143.50
-1.00 (-0.69%)
Closed
Oct 2, 2026
Day's Range
142.50149.50
52 wk Range
64.10155.00
Financial Statements - 6620 - Handa Pharmaceuticals, Inc.
Revenue
1.72B▲ 108.2%
Net Income
749.77M▲ 58.6%Net Margin 43.4%
EBITDA
1.10B▲ 125.1%
Free Cash Flow
226.54M▼ 53.8%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 1.72B | 830.67M | 1.10B | 197.67M | 29.23M | 28.85M |
| Cost of Goods | 267.48M | 1.17M | 1.30M | 18.71M | 1.46M | 1.42M |
| Gross Profit | 1.46B | 829.50M | 1.10B | 178.96M | 27.77M | 27.43M |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 934.18M | 418.05M | 693.42M | -88.12M | -253.88M | -317.47M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | - | - | - | - | - |
| Pre Tax Income | 936.97M | 479.17M | 792.48M | -43.15M | -260.80M | -320.44M |
| Income Tax | 187.20M | 6.42M | 65.60M | -3.13M | -13.13M | -38.34M |
| Net Income | 749.77M | 472.74M | 726.88M | -40.01M | -247.67M | -282.10M |
| EPS Basic | 4.85 | 3.37 | 5.41 | -0.32 | -2.06745 | -2.384361 |
| EPS Diluted | 4.83 | 3.35 | 5.41 | -0.32 | -2.06745 | -2.384361 |
| Basic Shares Outstanding | 154.49M | 140.48M | 134.35M | 125.56M | 119.58M | 118.78M |
| Diluted Shares Outstanding | 154.49M | 140.48M | 134.35M | 125.56M | 119.58M | 118.78M |
| Ebit | 939.17M | 479.66M | 792.70M | -42.86M | -260.56M | -319.99M |
| Ebitda | 1.10B | 490.09M | 805.15M | -27.68M | -225.40M | -259.50M |
| Net Income Continuous Operations | 936.97M | 479.17M | 792.48M | -43.15M | -260.80M | -320.44M |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
